Drug Repurposing Patent Applications Discussed in Upcoming ASSAY Special Issue

Winter is coming…. And that means that ASSAY and Drug Development Technologies will publish another special issue on drug repurposing. Here are the highlights of the PCT patent applications from Q2 and Q3/2016 that will be discussed.

  • X-Ray Contrast Agents for Ebola (WO/2016/054658, 3e Therapeutics Corp.)
  • A Heart Failure Drug for Myopathies and Respiratory ALS Complications (WO/2016/059287, Orion Corp.)
  • Filgrastim for Chronic Low-Level Brain Inflammation and Autism (WO/2016/064774, Chez M)
  • Stavudine for Neurodegenerative Conditions (WO/2016/067265, CNRS & INSERM)
  • A First-Generation Antifungal for Neurodevelopmental Disorders (WO/2016/072599, Academia Sinica et al.)
  • Clomiphene Isomers Differ in Their anti-Ebola Potential (WO/2016/089904, Repros Therapeutics, Inc.)
  • BTK Inhibitors for Blistering Autoimmune Diseases (WO/2016/100914, Principia Biopharma, Inc.)
  • Beta Blocker Gels for Diabetic Skin Ulcers (WO/2016/108130, Sun Pharmaceutical Industries Ltd.)
  • Kinase Inhibitors and Sulfasalazine for Reperfusion Injury (WO/2016/110160, China Medical University)
  • Desloratadine and Ebastine for Any Breast Cancer (WO/2016/116438, P.U.L.S. AB)
  • Rapamycin Immunosuppressants for an Ultra-Rare and Hideous Disease (WO/2016/121680, Kyoto University)
  • A Failed Autoimmune Disease Drug Candidate for Charcot-Marie-Tooth Disease (WO/2016/126707, Lam Therapeutics, Inc.
  • An HIV Drug for Steatohepatitis and Liver Fibrosis (WO/2016/130179, Tobira Therapeutics, Inc.)